The company's profit before tax was up 31% to $111.23 million compared with $84.6 million in the previous corresponding period (pcp) and the reported profit was $78.2 million, up 26% on the $62 million reported in the pcp.
Operating revenue of $425.2 million was 12% higher than the pcp.
The interim dividend increased 23% to 8.25c per share.
FPH chief executive Lewis Gradon said based on the positive first-half performance, the company was upgrading its full-year earnings guidance and expected full-year reported profit to be towards the middle of a $165 million to $170 million range.
Craigs Investment Partners broker Chris Timms said it was another strong result from FPH, slightly ahead of guidance.
''The underlying business continues to perform well in line with the thesis set out in our April door-stopper on respiratory care and the more recent update on obstructive sleep apnoea. This may provide some support to the stock following a period of weakness.''
In the hospital product group, operating revenue for the period grew 19% to $236.6 million.
Operating revenue in the homecare product group lifted 5% for the first half to $183.3 million. Masks used in the treatment of obstructive sleep apnoea (OSA) performed strongly, with revenue up 14% in constant currency.
Mr Gradon said the half had seen ''exceptional results'' from new applications in the hospital product group. Revenue grew 35% from those products in constant currency terms.
Several new clinical studies were published during the year which continued to demonstrate the effectiveness of the Optiflow nasal high-flow therapy, he said.
''This has encouraged uptake from clinicians around the world as the advantages of this therapy in terms of patient outcomes and economic benefits become increasingly evident.''
The gross margin increased 1.57% to 64.9% compared with the pcp, mainly due to favourable product mix, increased production in Mexico and supply chain efficiencies.
The company continued to invest in its growth programme, having signed an agreement for the purchase of a 15ha greenfields site in Mexico to enable further expansion of its manufacturing capabilities, he said.
Research and development investment increased 16% to $41.6 million, representing 9.8% of operating revenue for the period.
Looking ahead, Mr Gradon said the company had shown continued strength, buoyed by supportive research, a skilled global team and innovative products.
''Our longstanding objective is to double our constant currency operating revenue every five or six years.
''Our performance this financial year to date is consistent with that objective and the opportunities we see to assist more and more caregivers and their patients continue to give us confidence for the future.''
